Publications

Publications and Research

Explore publications and research from the Bath SPARC group.

  • Living with ankylosing spondylitis: an open response survey exploring physical activity experiences. Rouse, P. Standage, M. & Sengupta, R. Rheumatology Advances in Practice, Volume 3, Issue 2, 2019, rkz016, https://doi.org/10.1093/rap/rkz016
  • Evaluating patient-reported fatigue and serum biomarkers in axial spondyloarthritis. Reilly, E. McGrogan, A. & Sengupta, R. Rheumatology, keaa115, https://doi.org/10.1093/rheumatology/keaa115
  • Patient Perspectives on Self-Management Technologies for Chronic Fatigue Syndrome. Davies, T., Jones, S. & Kelly, R., 4 May 2019, Proceedings of the 2019 CHI Conference on Human Factors in Computing Systems. New York: Association for Computing Machinery, p. 1-13 13 p. 222. (CHI: Conference on Human Factors and Computing Systems). http://dx.doi.org/10.1145/3290605.3300452
  • Exploring the Future Role of Self-Tracking Data in the Rheumatology Clinic. Hue, W., Jones, S. & Sengupta, R., 5 Apr 2019, Healthcare of the Future. Bignens, S., Burkle, T., Lehmann, M., Denecke, K., Zetz, E., Holm, J. & Sariyar, M. (eds.). Biel/Bienne, Switzerland: IOS Press, p. 33-38 6 p. (Studies in Health Technology and Informatics; vol. 259). http://ebooks.iospress.nl/publication/51316
  • Supporting Collaborative Use of Self-Tracking Data in the Context of Healthcare and Chronic Conditions. Hue, W. 24 June 2019. DIS Doctoral Consortium. DIS ’19 Companion, June 24–28, 2019, San Diego, CA, USA. http://dx.doi.org/10.1145/3301019.332487 
  • Assessment of lumbar spinal mobility using inertial measurement units in axial spondyloarthritis. Franco, L., Ward, W., Sengupta, R. & Cazzola, D., 19 Sep 2018, Clinical and Experimental Rheumatology 2018. Vol. 36. p. 689-762 1 p. P164
  • Prognostic markers in axial spondyloarthritis (PROMISE) – cross sectional evaluation of serum biomarkers in axspa, mechanical back pain and healthy controls. Reilly, E., Fisher, C., Sengupta, R., FRI0193 Annals of the Rheumatic Diseases 2018;77:637. https://ard.bmj.com/content/77/Suppl_2/637.1
  • Prognostic markers in axial spondyloarthritis (PROMISE)-alpha 1 antitrypsin may identify axSpA patients at risk of uveitis. Reilly, E., McGrogan, A., Sengupta, R. Clinical and experimental rheumatology 2018;36(4):716
  • Prognostic markers in axial spondyloarthritis (PROMISE)-alpha 1 anti trypsin and beta 2 microglobulin may differentiate ankylosing spondylitis from non radiographic axSpA, mechanical back pain and healthy controls. Reilly, E, Fisher, C., McGrogan, A., Sengupta, R. Clinical and experimental rheumatology 2018;36(4):697
  • Disease activity predicts functional impairment and spinal mobility in axial spondyloarthritis. Williams, T., Wadeley, A., Cavill, C., Freeth, M., Hole, J., Sengupta, R., AB0891 Annals of the Rheumatic Diseases 2018;77:1570-1571
  • Is the delay from recognition of severe active axial spondyloarthritis to biologic disease modifying therapy initiation improving? Williams, T., Wadeley, A., Cavill, C., Freeth, M., Sengupta, R. Clinical and experimental rheumatology 2018;36(4):746
  • Axial spondyoarthritis-related quality of life improves significantly following initiation of biological disease-modifying therapy. Williams, T., Wadeley, A., Cavill, C., Freeth, M., Sengupta, R. Clinical and experimental rheumatology 2018;36(4):746
  • In axial spondyloarthritis, magnitude of improved disease activity after six months of biologic disease-modifying treatment may be more relevant to short-term functional outcome than achieving an inactive disease state. Williams, T., Wadeley, A., Cavill, C., Freeth, M., Sengupta, R. Rheumatology, 2019